Experienced regulatory help seems to be equally weighted with R & D, especially with this FDA regime. We've seen a lot of Bios with iffy science have tremendous runs because some co.s are good at working the committees.
Can't find much on Carrie-Lynn Langlais Furr, ok I really wanted to check her Linkedin profile to see if she was babelicious...I assume that might help as well...why not? Still with a small position and not whining yet, but they've made this move for a reason and apparently it wasn't to pump the pps as evidenced by market reaction this morning.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.